RT Journal Article
SR Electronic
T1 Metabologenomics identified fecal biomarkers for bowel movement regulation by <em>Bifidobacterium longum</em> capsules: an RCT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20041400
DO 10.1101/2020.03.23.20041400
A1 Y. Nakamura
A1 S. Suzuki
A1 S. Murakami
A1 K. Higashi
A1 N. Watarai
A1 Y. Nishimoto
A1 J. Umetsu
A1 C. Ishii
A1 Y. Ito
A1 Y. Mori
A1 M. Kohno
A1 T. Yamada
A1 S. Fukuda
YR 2020
UL http://medrxiv.org/content/early/2020/03/26/2020.03.23.20041400.abstract
AB Background Bifidobacterium longum supplementation can be used to regulate bowel movement; however, individuals vary in the response to B. longum treatment. One putative factor is the gut microbiota; recent studies have reported that the gut microbiota mediates diet or drug effects. Here, we investigated intestinal features related to B. longum effectiveness in increasing bowel movement frequency.Results A randomized, double-blind controlled crossover trial was conducted with twenty Japanese subjects selected from 50 participants. The subjects received a two-week dietary intervention consisting of B. longum in acid-resistant seamless capsules or similarly encapsulated starch powder. Bowel movement frequency was recorded daily, and time-series fecal collection was conducted for metabologenomic analyses. There were differences among subjects in B. longum intake-induced bowel movement frequency. The responders were predictable by machine learning based on the metabologenomic features of the fecal samples collected before B. longum intake. Between responders and non-responders, the abundances of nine bacterial genera and of three compounds were significantly different.Conclusions Thus, the gut microbiome and metabolome composition have a strong impact on B. longum supplementation effectiveness in increasing bowel movement frequency, and gut metabologenomics enables B. longum supplementation effect prediction before intake. These findings have implications for the development of personalized probiotic treatments.Trial registration UMIN-CTR, UMIN000018924. Registered 07 September 2015, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021894Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUMIN000018924Clinical Protocols https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021894 Funding StatementNone declared.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequencing dataset reported in this paper is available in the DDBJ Sequence Read Archive (DRA) repository (DRA006874; https://ddbj.nig.ac.jp/DRASearch/submission?acc=DRA006874). The metabolomic datasets by CE-TOFMS are included within the article and its additional files. https://ddbj.nig.ac.jp/DRASearch/submission?acc=DRA006874 IBSirritable bowel syndromeIBDinflammatory bowel diseaseMDSmultidimensional scalingFDRfalse discovery rateWAICWidely Applicable Information CriterionSRsstrong respondersWRsweak respondersNRsnonrespondersAUROCarea under the receiver operating characteristic curveSCFAsshort-chain fatty acidsESVsexact sequence variantsCSAD-camphor-10-sulfonic acidMCMCMarkov Chain Monte CarloPSRFpotential scale reduction factor